StockNews.com started coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT – Free Report) in a report published on Wednesday. The firm issued a hold rating on the stock.
Several other research analysts have also weighed in on ONCT. Northland Capmk lowered shares of Oncternal Therapeutics from a strong-buy rating to a hold rating in a research note on Thursday, September 12th. Brookline Capital Management reiterated a hold rating on shares of Oncternal Therapeutics in a research note on Thursday, September 12th. HC Wainwright dropped their price objective on shares of Oncternal Therapeutics from $19.00 to $18.00 and set a buy rating on the stock in a research note on Monday, August 12th. Finally, Northland Securities reiterated a market perform rating and issued a $2.00 price objective on shares of Oncternal Therapeutics in a research note on Thursday, September 12th. Four research analysts have rated the stock with a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of Hold and an average target price of $20.00.
Get Our Latest Stock Analysis on ONCT
Oncternal Therapeutics Price Performance
Oncternal Therapeutics (NASDAQ:ONCT – Get Free Report) last released its quarterly earnings data on Thursday, August 8th. The company reported ($2.89) earnings per share for the quarter, beating the consensus estimate of ($3.03) by $0.14. The firm had revenue of $0.80 million for the quarter, compared to analyst estimates of $0.24 million. Oncternal Therapeutics had a negative net margin of 1,948.70% and a negative return on equity of 136.10%. During the same quarter in the prior year, the business earned ($3.00) EPS. Sell-side analysts predict that Oncternal Therapeutics will post -11.43 EPS for the current fiscal year.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Oncternal Therapeutics stock. Pasadena Private Wealth LLC purchased a new position in shares of Oncternal Therapeutics, Inc. (NASDAQ:ONCT – Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 25,000 shares of the company’s stock, valued at approximately $190,000. Pasadena Private Wealth LLC owned about 0.84% of Oncternal Therapeutics as of its most recent SEC filing. Institutional investors own 16.05% of the company’s stock.
Oncternal Therapeutics Company Profile
Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.
Read More
- Five stocks we like better than Oncternal Therapeutics
- Where Do I Find 52-Week Highs and Lows?
- 3 Small-Cap Stocks on the Way to Bigger and Better Days
- 10 Best Airline Stocks to Buy
- MarketBeat Week in Review – 9/30 – 10/4
- 3 Tickers Leading a Meme Stock Revival
- Top Streaming Companies: Who’s Winning the Battle?
Receive News & Ratings for Oncternal Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncternal Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.